

Unverdorben, Martin

From: Michael Szwanek (402)437-4880 [Michael.Szwanek@mdsps.com]
Sent: Friday, January 24, 2003 1:43 PM
To: Hans-Juergen.Roethig@pmusa.com; bettie.l.nelson@pmusa.com;
martin.unverdorben@pmusa.com; qiwei.liang@pmusa.com
Cc: Kimberly Prchal; Megan McCrory; Robert Earl; Paul Johnson
Subject: Series K3 and K6 Short Term for Marlboro LIGHTS

Sensitivity: Confidential



AA02981_23JAN03 AA02981_23JAN03
Philip Morris... ATTACHMENTS_Ph.

All,

Attached is the first draft protocol and selected attachments for the Series K short term study dated Jan 23, 2003 for your review. The study is currently scheduled for the Feb 25, 2003 IRB requiring all documents final and ready for IRB submission by noon Wednesday, Feb 19, 2003. Please forward to any team member you wish to include in the review that I may have missed.

With the addition of a few specially requested study items, this study has become quite complex so could you please provide an extensive review to assure I have incorporated all events the way you intended? In particular, the summary of events table, objectives, study smoking supplies, urine collections, questionnaires (content and days scheduled), and statistical sections could use a thorough review.

ICF development for this study will begin upon release of this e-mail.

I will now devote my efforts to the Menthol protocol.

Have a good weekend.

Michael F. Szwanek, Pharm D., MBA
Section Head, Protocol Development and ICFs
MDS Pharma Services - Lincoln, NE
michael.szwanek@mdsps.com
(402) 437-4880